Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Sinovac Biotech ( (SVA) ) has provided an announcement.
On January 16, 2025, Sinovac Biotech Ltd. announced a Privy Council judgment validating the election of a new board proposed by shareholders during the 2018 Annual General Meeting. The ruling invalidates the company’s Rights Agreement and is set to become effective after a court order. Sinovac’s outgoing board is committed to a smooth transition, emphasizing the company’s history of significant shareholder value creation, highlighted by its substantial contribution to the global COVID-19 vaccine effort with 2.9 billion doses delivered worldwide.
More about Sinovac Biotech
Sinovac Biotech Ltd. is a China-based biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of vaccines. The company’s product portfolio includes vaccines for COVID-19, hepatitis A, influenza, and polio, among others. Sinovac has played a significant role in the global COVID-19 pandemic response with its CoronaVac® vaccine, which is approved in over 60 countries.
YTD Price Performance: 0.0%
Average Trading Volume: 8,227
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $460.3M
Find detailed analytics on SVA stock on TipRanks’ Stock Analysis page.
